GDP compliance and solar PV — the definitive guide for pharmaceutical warehouses
Good Distribution Practice (GDP — EC Directive 2013/C 68/01, UK equivalent) does not prohibit solar PV on pharmaceutical warehouses. The key compliance areas are: (1) Power resilience: GDP requires continuous maintenance of cold chain temperature (2-8°C controlled storage, -20°C frozen biological products). Solar PV operates in parallel with mains grid — it does not replace the grid connection as primary power source. The grid remains the primary supply; solar reduces grid import. No single point of failure is introduced. The design should include a written grid resilience assessment confirming that solar does not create dependency. (2) Installation methodology during active storage: roof works above active pharmaceutical storage must not contaminate product. A GDP-compatible installation methodology includes: sealed roof access (no open-hole penetrations over product zones during installation), HEPA filtration for any dust-generating activity on roof, air quality monitoring during installation, cold store temperature logging throughout installation period. (3) Environmental monitoring system independence: GDP cold chain monitoring must be independent. Solar monitoring should be installed as a separate data system with its own logger, communications, and cloud portal — zero cross-dependencies with the temperature monitoring system.
Cold chain self-consumption — why pharmaceutical warehouses have the best solar economics
Pharmaceutical cold chain warehouses maintain continuous electrical loads that make them strong solar consumers: (1) Cold room refrigeration plant (chiller, condenser, evaporator units): a 10,000 pallet WDA facility typically has 250-400 kW refrigeration electrical load running 24/7, year-round; (2) HVAC: clean room air handling units, pressure cascade systems for aseptic areas, HEPA filtration banks — typically 50-150 kW continuous; (3) Serialisation and track-and-trace: automated product verification lines, barcode readers, rejection mechanisms — 10-40 kW continuous; (4) Lighting and security: LED (typically 10-30 kW), CCTV, access control, environmental sensor arrays — 5-20 kW; (5) Cold chain monitoring infrastructure: temperature sensors, humidity monitors, data loggers, cloud uplinks — 2-5 kW. Total continuous baseload: 300-600 kW for a standard 10,000 pallet WDA site. Against a typical 500 kW PV system, self-consumption is 90-96%.
Key pharmaceutical warehouse locations and WDA operators for commercial solar
The Industrial Energy Transformation Fund is closed: its last application window shut on 19 April 2024, GOV.UK confirmed in July 2025 that no successor fund is planned, and solar PV was never an eligible technology.
Common questions
Does GDP prohibit solar PV on pharmaceutical warehouses?
No — GDP (Good Distribution Practice) does not prohibit solar PV. The compliance considerations are: power resilience (solar doesn't replace grid as primary cold chain power source), installation methodology (no contamination during roof works), and system independence (solar monitoring doesn't cross-link with GDP temperature monitoring). Ask the installer for a GDP-compatible installation methodology document and grid resilience assessment with every pharmaceutical cold chain install.
What self-consumption rate should pharmaceutical cold chain warehouses expect?
90-96% self-consumption. The continuous cold chain refrigeration load (250-400 kW for a 10,000 pallet WDA facility) runs 24/7. Combined with HVAC, serialisation, and monitoring infrastructure, the total 24/7 electrical baseload exceeds most solar system sizes — meaning virtually all generated electricity is consumed on-site.